Partnership plans trial of antidote to Factor Xa inhibitors

02/6/2013 | American City Business Journals

Portola Pharmaceuticals has entered a partnership with Bayer HealthCare and Johnson & Johnson's Janssen Pharmaceuticals to support a midstage clinical trial of PRT-4445, a reversal agent for anticoagulant Factor Xa inhibitor drugs. The study will involve patients treated with rivaroxaban.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC